
NRSN Stock Forecast & Price Target
NRSN Analyst Ratings
Bulls say
NeuroSense Therapeutics Ltd demonstrates a promising outlook driven by the successful results of its Phase 2b PARADIGM study, which showed a statistically significant 29.2% slowing of disease progression in patients treated with PrimeC. The company’s focus on neurodegenerative diseases and the favorable safety profile of its therapy, bolstered by biomarker-driven evidence of target engagement, enhance its potential for strategic partnerships, especially in North America and Europe. With the convergence of these clinical milestones and the opportunity for non-dilutive capital through regional commercial partnerships, NeuroSense is well-positioned for future growth and collaboration opportunities.
Bears say
NeuroSense Therapeutics Ltd is experiencing tightening cash flows, indicating potential liquidity challenges that could impair operational capabilities. The need for a capital raise suggests that the company may face difficulties in funding its ongoing development programs, such as PrimeC, which targets neurodegenerative diseases. These financial pressures could hinder the company's ability to advance its research and development efforts, negatively impacting investor sentiment and overall stock performance.
This aggregate rating is based on analysts' research of NeuroSense Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.
NRSN Analyst Forecast & Price Prediction
Start investing in NRSN
Order type
Buy in
Order amount
Est. shares
0 shares